We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Donald Lamm

Donald L Lamm MD

Clinical Professor, University of Arizona, Tucson; Director, BCG Oncology,Phoenix, Arizona

Dr. Donald Lamm is Clinical Professor at the University of Arizona and Director of BCG Oncology in Phoenix, Arizona. Dr. Lamm holds a medical degree from the University of California, Los Angeles (UCLA). Following his internship at the University of Oregon in Portland, he spent two years working as Director of the Colville Indian Health Service Clinic. Subsequently, he returned to California for a residency in surgery at UCLA and a residency in urology at the University of California, San Diego (UCSD).

Dr. Lamm is a pioneer in the field of immunotherapy for bladder cancer. During his urology residency, Dr. Lamm developed an animal model for bladder cancer and found that bacillus Calmette-Guérin (BCG) inhibited tumor growth. While at the University of Texas Health Science Center in San Antonio, he was awarded a National Cancer Institute (NCI) contract that resulted in the first randomized clinical trial to demonstrate the superiority of BCG immunotherapy over transurethral resection of the bladder tumour (TURBT) alone.  His subsequent research with the Southwest Oncology Group (SWOG) demonstrated that BCG was superior to Adriamycin.  This work, with the help of an American Urological Association (AUA) petition signed by 1,500 urologists, led to Food and Drug Administration (FDA) approval of TheraCys BCG for the treatment of carcinoma in situ in 1990.  Dr. Lamm’s continued work with SWOG proved the superiority of BCG versus mitomycin C and resulted in FDA approval of Tice BCG for the prevention of recurrence of papillary tumors. The SWOG 8507 trial using his 3-week, 3-year maintenance schedule further demonstrated the superiority of maintenance BCG over 6-week induction therapy alone for reducing disease progression.  Now in private genitourinary oncology practice, Dr. Lamm is working to develop improved immunotherapy and chemotherapy approaches for patients with bladder cancer.

Disclosures

1. Receive(d) Research Support from: Sanofi Pasteur